famotidine has been researched along with Esophagitis, Peptic in 38 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Esophagitis, Peptic: INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks." | 9.10 | [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage]. ( Li, IA; Vasil'ev, IuV, 2002) |
| "Two different doses of famotidine (20 mg twice a day versus 40 mg twice a day) were evaluated in a double-blind, randomized multicenter study in 474 symptomatic patients with erosive ulcerative reflux esophagitis." | 9.07 | Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. ( Dekker, W; Festen, HP; Wesdorp, IC, 1993) |
| "Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD)." | 8.78 | Famotidine in gastroesophageal reflux disease (GERD). ( Wesdorp, IC, 1992) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 6.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Famotidine was found to be safe and there were no serious clinical or laboratory adverse experiences." | 5.29 | Famotidine in the management of gastro-oesophageal reflux. ( Dubois, C; Lule, GN; Ogutu, EO; Okoth, FA; Pilczer, S, 1994) |
| "Lafutidine has a high endoscopic healing rate and improves symptoms of heartburn in patients with mild reflux esophagitis." | 5.14 | A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. ( Haruma, K; Kinoshita, Y; Kusano, M; Ohara, S, 2010) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks." | 5.10 | [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage]. ( Li, IA; Vasil'ev, IuV, 2002) |
| "Two different doses of famotidine (20 mg twice a day versus 40 mg twice a day) were evaluated in a double-blind, randomized multicenter study in 474 symptomatic patients with erosive ulcerative reflux esophagitis." | 5.07 | Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. ( Dekker, W; Festen, HP; Wesdorp, IC, 1993) |
| "Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD)." | 4.78 | Famotidine in gastroesophageal reflux disease (GERD). ( Wesdorp, IC, 1992) |
| "The clinical efficacy of famotidine has been clearly shown in the short- and long-term treatment of a number of acid-related diseases such as duodenal and gastric ulcer as well as in the acute management of reflux esophagitis." | 4.78 | Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. ( Dammann, HG, 1990) |
| "The effect of ranitidine 300 mg po given at 1800 h (famotidine 40 mg/cimetidine 800 mg) on the night time gastric pH was tested using longterm intragastric pH monitoring in 27 patients with and 32 patients without liver cirrhosis." | 3.67 | Frequent non-response to histamine H2-receptor antagonists in cirrhotics. ( Bode, JC; Klotz, U; Krishna, DR; Walker, S, 1989) |
| "Lafutidine was non-inferior to famotidine in healing of reflux esophagitis." | 2.80 | Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. ( Chang, YW; Choi, MG; Chun, HJ; Han, SW; Jeong, HY; Jung, HC; Jung, HY; Jung, JT; Kim, EH; Kim, HS; Kim, HY; Kim, JG; Lee, DH; Lee, OJ; Lee, ST; Lee, SW; Lee, YC; Park, JJ; Park, SH; Seol, SY; Youn, SJ, 2015) |
| "Lafutidine was significantly more effective than placebo (p=0." | 2.75 | [Efficacy evaluation of lafutidine for mild reflux esophagitis in Japanese patients]. ( Haruma, K; Kinoshita, Y; Kusano, M; Ohara, S, 2010) |
| "Omeprazole was superior to famotidine for treatment of upper abdominal symptoms in patients with reflux esophagitis, which suggested that gastric acid might be a cause not only of reflux symptoms, but also of ulcer symptoms and dysmotility symptoms such as epigastric pain and feeling of fullness in reflux esophagitis." | 2.74 | Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. ( Adachi, K; Fujimoto, K; Fujimura, Y; Fujisawa, T; Fuyuno, S; Haruma, K; Hori, K; Kido, S; Kin, Y; Kinoshita, Y; Kobori, M; Kusaka, M; Kusunoki, H; Matsunobu, A; Miwa, H; Nakamura, Y; Ono, N; Oza, N; Sugimoto, K; Tano, N; Tomita, T; Watanabe, Y; Yamauchi, R; Yuki, M, 2009) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 2.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| " We conducted a randomized single-blind study on the effects of 1 g sucralfate four times daily (n = 8), a mucosa-protective agent, versus 40 mg famotidine twice daily (n = 8), a new H2-blocker agent, administered for 12 weeks, in the treatment of peptic esophagitis (grades I to IV in accordance with Savary and Miller) refractory to a 6-month therapy with ranitidine at a dosage of 150 or 300 mg twice daily." | 2.67 | Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine. An endoscopic study. ( Bianchi Porro, G; Lazzaroni, M; Pace, F, 1991) |
| "Famotidine was found to be safe and there were no serious clinical or laboratory adverse experiences." | 1.29 | Famotidine in the management of gastro-oesophageal reflux. ( Dubois, C; Lule, GN; Ogutu, EO; Okoth, FA; Pilczer, S, 1994) |
| "The pharmacokinetics, pharmacodynamic effect and clinical efficacy of famotidine were studied in 10 patients with reflux oesophagitis Grades I and II." | 1.29 | Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. ( Dakshinamurty, KV; Dreuw, B; el Desoky, E; Gladziwa, U; Klotz, U; Wagner, S, 1993) |
| "Famotidine in high doses was well tolerated in this age group (mean 66." | 1.28 | High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study. ( Edge, DP, 1990) |
| "Famotidine was well tolerated." | 1.27 | Once-daily administration of famotidine for reflux esophagitis. ( Horikoshi, T; Kobayashi, S; Kogure, M; Kusano, M; Nishioka, T; Sekiguchi, T; Sugiyama, T, 1987) |
| "Famotidine was administered at about 1 to 2 mg/kg/day, two times daily to patients weighing more than 10 kg and three times daily to those weighing less than 10 kg." | 1.27 | Effect of a new H2-blocker, famotidine, in reflux esophagitis among severely handicapped children. ( Iwamoto, H; Miyake, S; Sugio, Y; Yamada, M; Yamashita, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.53) | 18.7374 |
| 1990's | 20 (52.63) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 5 (13.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahoshi, T | 1 |
| Kawanaka, H | 1 |
| Tomikawa, M | 1 |
| Saeki, H | 1 |
| Uchiyama, H | 1 |
| Ikeda, T | 1 |
| Shirabe, K | 1 |
| Hashizume, M | 1 |
| Maehara, Y | 1 |
| Kim, EH | 1 |
| Lee, YC | 1 |
| Chang, YW | 1 |
| Park, JJ | 1 |
| Chun, HJ | 1 |
| Jung, HY | 1 |
| Kim, HS | 1 |
| Jeong, HY | 1 |
| Seol, SY | 1 |
| Han, SW | 1 |
| Choi, MG | 1 |
| Park, SH | 1 |
| Lee, OJ | 1 |
| Jung, JT | 1 |
| Lee, DH | 1 |
| Jung, HC | 1 |
| Lee, ST | 1 |
| Kim, JG | 1 |
| Youn, SJ | 1 |
| Kim, HY | 1 |
| Lee, SW | 1 |
| Kusunoki, H | 1 |
| Kusaka, M | 1 |
| Kido, S | 1 |
| Yamauchi, R | 1 |
| Fujimura, Y | 1 |
| Watanabe, Y | 1 |
| Kobori, M | 1 |
| Miwa, H | 1 |
| Tomita, T | 1 |
| Kin, Y | 1 |
| Hori, K | 1 |
| Tano, N | 1 |
| Sugimoto, K | 1 |
| Nakamura, Y | 1 |
| Fujimoto, K | 1 |
| Oza, N | 1 |
| Matsunobu, A | 1 |
| Ono, N | 1 |
| Fuyuno, S | 1 |
| Kinoshita, Y | 5 |
| Adachi, K | 2 |
| Yuki, M | 1 |
| Fujisawa, T | 1 |
| Haruma, K | 3 |
| Ohara, S | 2 |
| Kusano, M | 4 |
| Fernández-Fernández, FJ | 1 |
| Sesma, P | 1 |
| Caínzos-Romero, T | 1 |
| Ferreira, L | 1 |
| Kawano, S | 1 |
| Murata, H | 1 |
| Tsuji, S | 1 |
| Kubo, M | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Kanda, T | 1 |
| Sato, T | 1 |
| Yoshihara, H | 1 |
| Masuda, E | 1 |
| Noguchi, M | 1 |
| Kashio, S | 1 |
| Ikeda, M | 1 |
| Kaneko, A | 1 |
| Vasil'ev, IuV | 1 |
| Li, IA | 1 |
| Hamamoto, N | 1 |
| Hashimoto, T | 1 |
| Hirakawa, K | 1 |
| Ishihara, S | 1 |
| Inoue, H | 1 |
| Taniura, H | 1 |
| Niigaki, M | 1 |
| Sato, S | 1 |
| Kushiyama, Y | 1 |
| Suetsugu, H | 1 |
| Miyake, T | 1 |
| Scarpignato, C | 1 |
| Mine, S | 2 |
| Iida, T | 2 |
| Tabata, T | 2 |
| Kishikawa, H | 1 |
| Tanaka, Y | 2 |
| Umeda, N | 1 |
| Miki, K | 1 |
| Hoshino, E | 1 |
| Yamashita, Y | 1 |
| Chihara, K | 1 |
| Chiba, T | 1 |
| Okoth, FA | 1 |
| Lule, GN | 1 |
| Ogutu, EO | 1 |
| Pilczer, S | 1 |
| Dubois, C | 1 |
| Wesdorp, IC | 2 |
| Dekker, W | 1 |
| Festen, HP | 1 |
| Simon, TJ | 1 |
| Berlin, RG | 1 |
| Tipping, R | 1 |
| Gilde, L | 1 |
| Gladziwa, U | 1 |
| Wagner, S | 1 |
| Dakshinamurty, KV | 1 |
| el Desoky, E | 1 |
| Dreuw, B | 1 |
| Klotz, U | 2 |
| Ahmed, W | 1 |
| Qureshi, H | 1 |
| Alam, SE | 1 |
| Zuberi, SJ | 1 |
| Soga, T | 1 |
| Matsuura, M | 1 |
| Kodama, Y | 1 |
| Fujita, T | 1 |
| Sekimoto, I | 1 |
| Nishimura, K | 1 |
| Yoshida, S | 1 |
| Kutsumi, H | 1 |
| Fujimoto, S | 1 |
| Sugano, K | 1 |
| Wilhelmsen, I | 1 |
| Hatlebakk, JG | 1 |
| Olafsson, S | 1 |
| Berstad, A | 1 |
| Fujisaki, T | 1 |
| Matsuoka, H | 1 |
| Yamada, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Aibe, T | 1 |
| Endo, M | 1 |
| Sugihara, K | 1 |
| Ivanova, S | 1 |
| Gavrilova, V | 1 |
| Dimitrov, L | 1 |
| Kratochvil, P | 1 |
| Brandstätter, G | 1 |
| Janisch, P | 1 |
| Pace, F | 2 |
| Lazzaroni, M | 1 |
| Bianchi Porro, G | 2 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Satoh, H | 1 |
| Sangaletti, O | 1 |
| Sekiguchi, T | 2 |
| Nishioka, T | 2 |
| Matsuzaki, T | 1 |
| Sugiyama, M | 1 |
| Horikoshi, T | 2 |
| Toki, M | 1 |
| Ohwada, T | 1 |
| Kobayashi, S | 2 |
| Bovero, E | 1 |
| Poletti, M | 1 |
| Iaquinto, G | 1 |
| Giardulo, N | 1 |
| Zambelli, A | 1 |
| Pisano, G | 1 |
| Cheli, R | 1 |
| Oderda, G | 1 |
| Dell'Olio, D | 1 |
| Forni, M | 1 |
| Farina, L | 1 |
| Tavassoli, K | 1 |
| Ansaldi, N | 1 |
| Dammann, HG | 1 |
| Edge, DP | 1 |
| Walker, S | 1 |
| Krishna, DR | 1 |
| Bode, JC | 1 |
| Kogure, M | 1 |
| Sugiyama, T | 1 |
| Miyake, S | 1 |
| Yamada, M | 1 |
| Iwamoto, H | 1 |
| Yamashita, S | 1 |
| Sugio, Y | 1 |
| Pounder, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -[NCT00229424] | Phase 3 | 325 participants | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for famotidine and Esophagitis, Peptic
| Article | Year |
|---|---|
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Famotidine in gastroesophageal reflux disease (GERD).
Topics: Cimetidine; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; Humans; Ranitidine | 1992 |
Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview.
Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Humans; Product Surveilla | 1990 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
23 trials available for famotidine and Esophagitis, Peptic
| Article | Year |
|---|---|
Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Topics: Aged; Esophageal and Gastric Varices; Esophageal pH Monitoring; Esophagitis, Peptic; Famotidine; Fem | 2013 |
Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.
Topics: Acetamides; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; | 2015 |
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Histamine H2 Antagonists; H | 2009 |
[Efficacy evaluation of lafutidine for mild reflux esophagitis in Japanese patients].
Topics: Acetamides; Adult; Aged; Asian People; Esophagitis, Peptic; Famotidine; Female; Histamine H2 Antagon | 2010 |
A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
Topics: Acetamides; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Heartburn; | 2010 |
Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
Topics: Aged; Drug Evaluation; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Ga | 2002 |
[Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastroesophagea | 2002 |
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Topics: Adult; Aged; Aged, 80 and over; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Histamine H2 | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies | 1995 |
[Comparison of the effects between standard doses of H2-blocker (famotidine 20mg b.d.) and proton pump inhibitor (omeprazole 20mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Esophagitis, Peptic; Esophagus; Famotidine; Female; Gastri | 1994 |
Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Esoph | 1993 |
Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.
Topics: Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Famotidine; Female; Humans; | 1993 |
Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?
Topics: Alcohol Drinking; Case-Control Studies; Endoscopy, Digestive System; Enzyme Inhibitors; Esophagitis, | 1999 |
On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastric | 1999 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph | 2000 |
[Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; En | 2000 |
[Intravenous treatment with quamatel in reflux-esophagus and erosive gastritis].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastritis; Gast | 2000 |
[Treatment of mild to moderate reflux esophagitis with the H2-blocker famotidine].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Esophagitis, Peptic; Esophagus; Famo | 1992 |
Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine. An endoscopic study.
Topics: Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Humans; Ma | 1991 |
Famotidine in the management of acid-reflux oesophagitis: a multicentre study.
Topics: Adult; Aged; Biopsy; Esophagitis, Peptic; Esophagoscopy; Esophagus; Famotidine; Female; Humans; Hydr | 1990 |
Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid.
Topics: Adolescent; Alginates; Antacids; Biopsy; Child; Child, Preschool; Drug Combinations; Esophagitis, Pe | 1990 |
Histamine H2-receptor antagonists.
Topics: Animals; Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Famotidine; Histamine H2 Ant | 1988 |
12 other studies available for famotidine and Esophagitis, Peptic
| Article | Year |
|---|---|
[Hypomagnesemia related to the use of omeprazole with negative result for mutation in the TRPM6 gene].
Topics: Aged; Alcoholism; Esophagitis, Peptic; Famotidine; Histamine H2 Antagonists; Humans; Intestinal Abso | 2011 |
Famotidine in the management of gastro-oesophageal reflux.
Topics: Adult; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Famotidine; Female; Follow-Up Studies; Gast | 1994 |
Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.
Topics: Adult; Aged; Esophagitis, Peptic; Famotidine; Female; Half-Life; Humans; Hydrogen-Ion Concentration; | 1993 |
Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Esophagitis, Peptic; Esoph | 1995 |
Optimum management of mild esophagitis in Japan.
Topics: Anti-Ulcer Agents; Disease Management; Esophagitis, Peptic; Famotidine; Helicobacter Infections; Hel | 1999 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists.
Topics: Esophagitis, Peptic; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1990 |
Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
Topics: Adult; Aged; Chronic Disease; Cisapride; Esophagitis, Peptic; Esophagus; Famotidine; Female; Humans; | 1991 |
High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Drug Administration Schedule; Esophagitis, Peptic | 1990 |
Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
Topics: Anti-Ulcer Agents; Cimetidine; Esophagitis, Peptic; Famotidine; Female; Gastric Acidity Determinatio | 1989 |
Once-daily administration of famotidine for reflux esophagitis.
Topics: Adolescent; Adult; Aged; Drug Administration Schedule; Esophagitis, Peptic; Esophagoscopy; Famotidin | 1987 |
Effect of a new H2-blocker, famotidine, in reflux esophagitis among severely handicapped children.
Topics: Adolescent; Child; Child, Preschool; Disabled Persons; Esophagitis, Peptic; Famotidine; Female; Hema | 1987 |